| Year |
Citation |
Score |
| 2023 |
Mu HY, Lin CM, Chu LA, Lin YH, Li J, Yu Liu C, Huang HC, Cheng SL, Lee TY, Lee HM, Chen HM, Tsai YJ, Chen Y, Huang JH. Ex Vivo Evaluation of Combination Immunotherapy Using Tumor-Microenvironment-on-Chip. Advanced Healthcare Materials. e2302268. PMID 37748773 DOI: 10.1002/adhm.202302268 |
0.576 |
|
| 2023 |
Lee TY, Lu HH, Cheng HT, Huang HC, Tsai YJ, Chang IH, Tu CP, Chung CW, Lu TT, Peng CH, Chen Y. Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis. Journal of Controlled Release : Official Journal of the Controlled Release Society. 354: 417-428. PMID 36627025 DOI: 10.1016/j.jconrel.2022.12.059 |
0.703 |
|
| 2023 |
Magoling BJA, Wu AY, Chen YJ, Wong WW, Chuo ST, Huang HC, Sung YC, Hsieh HT, Huang P, Lee KZ, Huang KW, Chen RH, Chen Y, Lai CP. Membrane Protein Modification Modulates Big and Small Extracellular Vesicle Biodistribution and Tumorigenic Potential in Breast Cancers in vivo. Advanced Materials (Deerfield Beach, Fla.). e2208966. PMID 36609913 DOI: 10.1002/adma.202208966 |
0.763 |
|
| 2022 |
Hsieh HT, Huang HC, Chung CW, Chiang CC, Hsia T, Wu HF, Huang RL, Chiang CS, Wang J, Lu TT, Chen Y. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma. Journal of Controlled Release : Official Journal of the Controlled Release Society. 352: 920-930. PMID 36334859 DOI: 10.1016/j.jconrel.2022.10.047 |
0.783 |
|
| 2022 |
Cheng HT, Huang HC, Lee TY, Liao YH, Sheng YH, Jin PR, Huang KW, Chen LH, Chen YT, Liu ZY, Lin TC, Wang HC, Chao CH, Juang IP, Su CT, et al. Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis. Journal of Controlled Release : Official Journal of the Controlled Release Society. 346: 169-179. PMID 35429575 DOI: 10.1016/j.jconrel.2022.04.004 |
0.705 |
|
| 2022 |
Hong YH, Narwane M, Liu LY, Huang YD, Chung CW, Chen YH, Liao BW, Chang YH, Wu CR, Huang HC, Hsu IJ, Cheng LY, Wu LY, Chueh YL, Chen Y, et al. Enhanced Oral NO Delivery through Bioinorganic Engineering of Acid-Sensitive Prodrug into a Transformer-like DNIC@MOF Microrod. Acs Applied Materials & Interfaces. PMID 35019259 DOI: 10.1021/acsami.1c21409 |
0.434 |
|
| 2021 |
Huang HC, Sung YC, Li CP, Wan D, Chao PH, Tseng YT, Liao BW, Cheng HT, Hsu FF, Huang CC, Chen YT, Liao YH, Hsieh HT, Shih YC, Liu IJ, et al. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours. Gut. PMID 34921062 DOI: 10.1136/gutjnl-2021-325180 |
0.724 |
|
| 2020 |
Chu MY, Huang HC, Li EM, Xu LY. CypA: a Potential Target of Tumor Radiotherapy and/or Chemotherapy. Current Medicinal Chemistry. PMID 33121398 DOI: 10.2174/0929867327666201029161055 |
0.307 |
|
| 2020 |
Wu AY, Sung YC, Chen YJ, Chou ST, Guo V, Chien JC, Ko JJ, Yang AL, Huang HC, Chuang JC, Wu S, Ho MR, Ericsson M, Lin WW, Cheung CHY, et al. Multiresolution Imaging Using Bioluminescence Resonance Energy Transfer Identifies Distinct Biodistribution Profiles of Extracellular Vesicles and Exomeres with Redirected Tropism. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). 7: 2001467. PMID 33042758 DOI: 10.1002/Advs.202001467 |
0.732 |
|
| 2020 |
Shang HS, Chen KW, Chou JS, Peng SF, Chen YL, Chen PY, Huang HC, Lu HF, Chang HY, Shih YL, Huang WW. Casticin Inhibits Growth of Xenograft Tumors of Human Oral Cancer SCC-4 Cells. In Vivo (Athens, Greece). 34: 2461-2467. PMID 32871773 DOI: 10.21873/invivo.12061 |
0.304 |
|
| 2020 |
Juang JJ, Liu YB, Chen CJ, Yu QY, Chattopadhyay A, Lin LY, Chen WJ, Yu CC, Huang HC, Ho LT, Lai LP, Hwang JJ, Lin TT, Liao MC, Chen JJ, et al. Validation and Disease Risk Assessment of Previously Reported Genome-Wide Genetic Variants Associated with Brugada Syndrome: SADS-TW BrS Registry. Circulation. Genomic and Precision Medicine. PMID 32490690 DOI: 10.1161/CIRCGEN.119.002797 |
0.483 |
|
| 2020 |
Huang KW, Hsu FF, Qiu JT, Chern GJ, Lee YA, Chang CC, Huang YT, Sung YC, Chiang CC, Huang RL, Lin CC, Dinh TK, Huang HC, Shih YC, Alson D, et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Science Advances. 6: eaax5032. PMID 31998834 DOI: 10.1126/Sciadv.Aax5032 |
0.534 |
|
| 2017 |
Liu CH, Chern GG, Hsu FF, Huang KW, Sung YC, Huang HC, Qiu JT, Wang SK, Lin CC, Wu CH, Wu HC, Liu JY, Chen Y. A multifunctional nanocarrier for efficient TRAIL-based gene therapy against hepatocellular carcinoma with desmoplasia. Hepatology (Baltimore, Md.). PMID 28885731 DOI: 10.1002/Hep.29513 |
0.717 |
|
| Show low-probability matches. |